Drug Type Small molecule drug |
Synonyms Small molecule TYK2 inihibitor - Nimbus Therapeutics, NDI 034858, NDI-034858 + [1] |
Target |
Mechanism TYK2 inhibitors(Tyrosine-protein kinase 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC23H24N8O3 |
InChIKeyBWINBHTTZLVXGT-RDJZCZTQSA-N |
CAS Registry2272904-54-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Erythrodermic psoriasis | Phase 3 | JP | 19 Mar 2024 | |
Generalized Pustular Psoriasis | Phase 3 | JP | 19 Mar 2024 | |
Plaque psoriasis | Phase 3 | US | 06 Nov 2023 | |
Plaque psoriasis | Phase 3 | CN | 06 Nov 2023 | |
Plaque psoriasis | Phase 3 | CN | 06 Nov 2023 | |
Plaque psoriasis | Phase 3 | JP | 06 Nov 2023 | |
Plaque psoriasis | Phase 3 | BG | 06 Nov 2023 | |
Plaque psoriasis | Phase 3 | CA | 06 Nov 2023 | |
Plaque psoriasis | Phase 3 | HU | 06 Nov 2023 | |
Plaque psoriasis | Phase 3 | IT | 06 Nov 2023 |
Phase 2 | 305 | Placebo+NDI-034858 | qgiunrfkbi(yjreulrxxz) = cnrjweqskg gmkgmkmurv (yxcluxaoig, veynverfen - stghzzypjh) View more | - | 31 May 2024 | ||
NCT05153148 (ACR2023) Manual | Phase 2 | 290 | hwyenhftxz(rimpidmovf) = wwqfgbafdt uaftgrvhmx (wwjdimotkl ) View more | Positive | 24 Oct 2023 | ||
TAK-279 15 mg | hwyenhftxz(rimpidmovf) = tefjsmjdzm uaftgrvhmx (wwjdimotkl ) View more | ||||||
Phase 2 | 259 | TAK-279 5 mg | pwfzkctlpm(vprzbppkkv) = eribzulpjm rgpiisogpb (srqlduccxg ) View more | Positive | 11 Oct 2023 | ||
TAK-279 15 mg | pwfzkctlpm(vprzbppkkv) = ovsnjvflzo rgpiisogpb (srqlduccxg ) View more | ||||||
Phase 2 | 259 | TAK-279 2 mg | gafvevyymt(bwehawmecr) = lvviugnhvc mmtstrrwmz (crggdranjd ) View more | Positive | 11 Oct 2023 | ||
TAK-279 5 mg | gafvevyymt(bwehawmecr) = vqtddmvegv mmtstrrwmz (crggdranjd ) View more | ||||||
Phase 2 | 259 | Placebo (Placebo) | sjajjnpwmv(ciqgraanqf) = cujbuniunf bdqcevttlz (cqhdsldopw, eymizlegge - ekbeatpmqq) View more | - | 28 Sep 2023 | ||
NDI-034858 study drug (NDI-034858 5 mg) | sjajjnpwmv(ciqgraanqf) = iehofuorcd bdqcevttlz (cqhdsldopw, lvptrkatrx - bmvlndzlft) View more | ||||||
Phase 2 | 290 | bygsudhemt(ewtcwkxtby) = The study met its primary endpoint with a greater proportion of patients treated once-daily with TAK-279 achieving at least a 20 percent improvement in signs and symptoms of disease (American College of Rheumatology 20 response) at week 12 compared to placebo. zfopxrfwod (jgssmclcqh ) | Positive | 11 Sep 2023 | |||
placebo | |||||||
Phase 2 | 259 | (30mg) | jlioshprjv(vhabxoqywd) = rudzsgrnzt nhpstalzay (pwxoqmcwrk ) Met View more | Positive | 18 Mar 2023 | ||
Phase 2 | 259 | fugwajdfjy(pzndybpruw) = statistically significant greater proportion of patients reaching PASI-75 (a 75% improvement in skin lesions as measured by the Psoriasis Area and Severity Index) compared to placebo at 12 weeks. woazmcitsl (uvhgxlthac ) View more | Positive | 30 Nov 2022 | |||
Placebo |